Integra Therapeutics Secures €10.5 Million from European Commission for FiCAT Advanced Therapies Platform

Integra Therapeutics, a biotech company specializing in gene writing tools, has been awarded a grant and equity investment totaling €10.5 …

Continue ›››

Oxford Drug Design Validates Novel Oncology Therapeutic Mechanism

Oxford Drug Design, an AI-driven drug discovery company, has achieved successful in vivo validation of its novel oncology therapeutic mechanism …

Continue ›››

Bioptimus Introduces H-optimus-0: An Open-Source AI Model for Pathology

French startup Bioptimus has released H-optimus-0, the largest open-source AI foundation model for pathology. With 1.1 billion parameters, this model …

Continue ›››

Lantern Pharma Advances Development of Molecular Diagnostic for Oncology Clinical Trials

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, has reached a milestone in the development of a diagnostic tool for …

Continue ›››

Concr Launches VISION Trial Using Digital Twins for Predicting Breast Cancer Outcomes

Concr has initiated the recruitment of patients for the VISION trial, an observational clinical study designed to evaluate Concr's predictive …

Continue ›››

Myricx Bio Secures £90m Series A Funding to Progress NMTi-ADC Therapeutics into Clinical Trials

Myricx Bio, a UK-based biotechnology company specializing in novel antibody-drug conjugates (ADCs), has raised £90 million ($114 million) in a …

Continue ›››

FDA Approves Signet Therapeutics' IND Application for sigx1094 in Diffuse Gastric Cancer

Signet Therapeutics, a biotechnology company specializing in targeted cancer therapy, has received FDA approval for its Investigational New Drug (IND) …

Continue ›››

Evaxion Biotech Receives Positive Feedback on Patent Application for Personalized Vaccine Targets

Evaxion Biotech A/S, a clinical-stage TechBio company known for its AI-Immunology™ powered vaccines, has received favorable feedback regarding its recent …

Continue ›››

Lantern Pharma Receives Japanese Patent for Oncology Drug Candidate LP-284

Lantern Pharma Inc., an AI-driven company focused on oncology drug development, has announced that the Japan Patent Office (JPO) has granted …

Continue ›››

Envisagenics Secures $25 Million Series B Funding to Advance RNA Splicing Therapeutics

Envisagenics, an AI-enabled biotechnology firm specializing in RNA splicing therapeutics, has announced the completion of its Series B funding round. …

Continue ›››

Merck KGaA Partners with Biolojic Design for $376M Antibody-Drug Conjugate Development

Merck KGaA has entered into a collaboration with Biolojic Design to develop new oncology and immunology therapeutics using Biolojic’s AI-driven …

Continue ›››

Paige Introduces Multi-Modal AI for Enhanced Precision Oncology and Drug Discovery

Paige, a provider of digital pathology solutions and AI applications, has launched a new service line leveraging its Foundation Models. …

Continue ›››